NEWS AND INSIGHTS

Inspiring New Stories

Halozyme provides disruptive drug delivery solutions with the goal of improving patient experiences and outcomes that can enhance the competitiveness of emerging and established therapies. To catch up on our latest news, updates and Industry Insights, please review the links below:

Press Releases

Halozyme to Present at Upcoming Investor Conferences

08/31/2023

Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

08/29/2023

HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS

08/08/2023

Halozyme To Report Second Quarter 2023 Financial and Operating Results

07/25/2023

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

07/17/2023

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

07/13/2023

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis

06/20/2023

Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

06/06/2023

HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS

05/09/2023

Halozyme to Present at Upcoming Investor Conferences

05/03/2023

View All Press Releases

All 3

All 3 /Company Updates 1 /Executive Insights 1 /Values Series 1

Insights Value Series: Introduction

April 5, 2022/by ehennes

Inspire Week – Highlighting the Importance of Recharging the Mind, Body and Spirit

August 9, 2021/by David Anderson

You’re A Small Biotech — How Should You Implement A Pharmacovigilance System?

January 28, 2021/by David Anderson

Press Releases

05/21/21
Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE®
05/10/21
Halozyme Reports First Quarter 2021 Results
04/29/21
Halozyme to Present at BofA Securities 2021 Virtual Health Care Conference
04/20/21
Halozyme To Host First Quarter 2021 Financial Results Webcast And Conference Call
02/24/21
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027
02/23/21
Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027
02/23/21
Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results
02/10/21
Halozyme To Host Fourth Quarter And Full Year 2020 Financial Results Webcast And Conference Call
01/15/21
Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis
01/11/21
Halozyme Provides 2021 Financial Guidance Highlighted By Strong Revenue And EPS Growth
01/04/21
Halozyme To Present Virtually At The 39th Annual J.P. Morgan Healthcare Conference